Objective: To evaluate clinical outcome, prognostic factors and chronic morbidity with radiotherapy for vaginal cancer treatment.
Materials And Methods: 68 patients with vaginal cancer treated by radical or adjuvant radiotherapy (RT) were selected. Five with rare subtypes of histopathology and 8 with adenocarcinoma were excluded from this study. 76.4% of the remainder had early-stage diseases (stage I: 14, II: 28, III: 9, and IV: 4). The patients in the years from which they were treated were almost evenly distributed (1st 5 years: 13, 2nd: 14, 3rd: 16, and 4th: 12). There were four treatment groups: external beam radiotherapy (EBRT) alone (n=18), brachytherapy (BT) alone (n=4), EBRT and BT (n=30), and surgery plus RT (n=3).
Results: Median follow-up was 50.3 months ranging from 3 to 213 months. 5-year overall survival (OS) was 55.6%, disease-specific survival (DSS) was 77.3%, disease-free survival was 74.2%, and local control was 87.7%. Independent prognostic factors for DSS and OS were tumor stage, site and size (p<0.05). Late radiation toxicity was minimal in the bladder (4.6%) and bowel (4.6%). Vaginal morbidity was observed in 35 patients (63.6%). It was lowest in the BT alone (0%), and highest in the EBRT and BT group (82.1%), especially for those received more than 70 Gy (p=0.05, Odds ratio=4.64, 95% confidence interval: 1.01-21.65).
Conclusion: This retrospective review suggested that tumor stage, site, and size were important prognostic factors in patients with vaginal cancer. Higher radiation dose was associated with more frequent vaginal toxicity.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ygyno.2008.07.007 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The role of lipids and lipids lowering drugs in human papillomavirus (HPV) and HPV-associated cancers.
Infect Agent Cancer
January 2025
Shahid Beheshti University of Medical Sciences, Hamadan University of Medical Sciences, Hamadan, Iran.
Both women and men are now confronted with the grave threat of cancers caused by the human papillomavirus (HPV). It is estimated that 80% of women may encounter HPV over their lives. In the preponderance of cases involving anal, head and neck, oral, oropharyngeal, penile, vaginal, vulvar, and cervical malignancies, high-risk HPV (HR-HPV) is the causative agent.
View Article and Find Full Text PDFEffectiveness of Pelvic Floor Muscle and Education-based Therapies on Bladder, Bowel, Vaginal, Sexual, Psychological Function, Quality of Life, and Pelvic Floor Muscle Function in Females Treated for Breast Cancer: A Systematic Review.
Curr Oncol Rep
January 2025
Melbourne School of Health Sciences, The University of Melbourne, The Royal Women's Hospital, Melbourne; Mercy Hospital for Women, Melbourne, VIC, Australia.
Purpose Of Review: Breast malignancy is the most common cancer in females. Symptoms of pelvic floor disorders and sexual dysfunction secondary to systemic cancer treatment may occur. Non-surgical, non-pharmaceutical conservative therapies, namely pelvic floor muscle (PFM) and education-based therapies, could be beneficial to reduce these symptoms in this population.
View Article and Find Full Text PDFSpatial Epidemiology of Human Papillomavirus Screening Coverage in Mexico, 2013-2019.
Asian Pac J Cancer Prev
January 2025
Directorate of Medical Benefits, Mexican Social Security Institute, Mexico City, Mexico.
Objective: We aimed to assess the coverage of a Human Papillomavirus (HPV) screening program for each of the 32 federal states of Mexico, as well as the spatial patterns for HPV infections from 2013 to 2019.
Methods: We conducted an exploratory, ecological study on data from a national health program in Mexico during 2013-2019. Adjusted rates per 100,000 females aged 25-64 years were estimated and georeferenced at the national and state level to assess the coverage of the screening program and positive detections of HPV infections.
International Urogynecology Consultation Chapter 3 Committee 1 - Pessary Management.
Int Urogynecol J
January 2025
Division of Health Services Research & Implementation Science, Southern California Permanente Medical Group, San Diego, CA, USA.
Introduction And Hypothesis: This manuscript is part of the International Urogynecological Consultation (IUC) on Pelvic Organ Prolapse (POP), Chapter 3, Committee 1 focusing on pessary management of POP.
Methods: A narrative review was conducted by an international, multi-disciplinary group of clinicians working in the field of pelvic health following a search of the literature using the MeSH terms "pelvic organ prolapse" OR "urogenital prolapse" OR "vaginal prolapse" OR "uterovaginal prolapse" AND "pessary" OR "support device" OR "intravaginal device." Relevant studies, as determined after review using the Covidence manuscript review platform, were included.
Vacuolated Parabasal Cells in Papanicolaou Smears Are Cellular Changes Caused by Human Papillomavirus 16 Infection.
J Med Virol
February 2025
Department of Medical Technology, Faculty of Health Sciences, Kyorin University, Tokyo, Japan.
In cervical cancer screening, cytology is used as a triage test to refer high-risk human papillomavirus (HR-HPV)-positive women for colposcopy, but its accuracy is inadequate. The present study aimed to demonstrate that the presence of atypical cells with large vacuoles in the cytoplasm of parabasal cells, referred to as vacuolated parabasal cells (VPCs), which are observed in the Pap smears of HPV-positive women, is associated with specific HPV genotypes. Among 2175 patients, 310 with a single HR-HPV infection and cytological diagnosis of high-grade squamous intraepithelial lesions (HSIL) or atypical squamous cells not excluding HSIL (ASC-H) were included, of which 86 were infected with HPV16.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!